Examining molecules in placentas of patients with placenta previa and percreta
INVESTIGATION OF GLYCOPROTEIN, FIBER AND GROWTH FACTOR EXPRESSIONS IN PATIENTS WITH PLACENTA PREVIA, PLACENTA PERFORATA IN THE 3RD TRIMESTER OF PREGNANCY
This study looks at blood and tissue samples from pregnant women with placenta previa and placenta percreta to see what molecules are involved, which could help improve care for these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 48 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Celal Bayar University Academic / other |
| Locations | 1 site (Manisa) |
| Trial ID | NCT06849349 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with placenta previa and placenta percreta, conditions that can lead to severe complications during pregnancy and delivery. Blood and tissue samples will be collected from participants during hospitalization for delivery, specifically after the umbilical cord is clamped. These samples will be analyzed to understand the molecular characteristics associated with these conditions. The study aims to gather data that could inform future management and treatment strategies for affected patients.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women aged 18-50 with healthy pregnancies under 37 weeks who are literate in Turkish.
Not a fit: Patients with high-risk pregnancies or those with additional diseases or complications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for patients with placenta previa and percreta, potentially reducing maternal and fetal morbidity.
How similar studies have performed: While there is ongoing research in this area, the specific approach of examining molecular characteristics in placentas of patients with these conditions is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy pregnancy under 37 weeks * Age range 18-50 * Being literate in Turkish * Not having any additional disease * Agreeing to participate in the study Exclusion Criteria: * High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.) * Multiple pregnancy * Pregnant women under the age of 18 * Smoking * Medication use (excluding routinely used food supplements during pregnancy) * Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.) * Immunosuppressive use * Presence of active or chronic infection * Presence of active or chronic inflammatory disease * Patients who gave birth at an external center or later chose to withdraw from the study * Patients who did not have any exclusion criteria at the time of Placenta percrata/ placenta previa or when blood was drawn for the control group, but who later developed any exclusion criteria. * Premature birth of patients included in the control group
Where this trial is running
Manisa
- Manisa Celal Bayar University — Manisa, Turkey (Türkiye) (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.